These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 22551628)

  • 1. Bidirectional fluorescence properties of pyrene-based peroxisome proliferator-activated receptor (PPAR) α/δ dual agonist.
    Ban S; Oyama T; Kasuga J; Ohgane K; Nishio Y; Morikawa K; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2012 Jun; 20(11):3460-4. PubMed ID: 22551628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peroxisome proliferator-activated receptors (PPARs) have multiple binding points that accommodate ligands in various conformations: phenylpropanoic acid-type PPAR ligands bind to PPAR in different conformations, depending on the subtype.
    Kuwabara N; Oyama T; Tomioka D; Ohashi M; Yanagisawa J; Shimizu T; Miyachi H
    J Med Chem; 2012 Jan; 55(2):893-902. PubMed ID: 22185225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based design and synthesis of fluorescent PPARalpha/delta co-agonist and its application as a probe for fluorescent polarization assay of PPARdelta ligands.
    Araya Y; Kasuga J; Toyota K; Hirakawa Y; Oyama T; Makishima M; Morikawa K; Hashimoto Y; Miyachi H
    Chem Pharm Bull (Tokyo); 2008 Sep; 56(9):1357-9. PubMed ID: 18758120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of the critical amino acids involved in the peroxisome proliferator-activated receptor (PPAR) delta selectivity of phenylpropanoic acid-derived agonists.
    Kasuga J; Oyama T; Nakagome I; Makishima M; Hirono S; Morikawa K; Hashimoto Y; Miyachi H
    ChemMedChem; 2008 Nov; 3(11):1662-6. PubMed ID: 18924220
    [No Abstract]   [Full Text] [Related]  

  • 5. Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR α/γ Dual Agonist.
    Honda A; Kamata S; Satta C; Machida Y; Uchii K; Terasawa K; Nemoto A; Oyama T; Ishii I
    Biol Pharm Bull; 2021; 44(9):1210-1219. PubMed ID: 34471049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor alpha/delta dual agonists.
    Kasuga J; Makishima M; Hashimoto Y; Miyachi H
    Bioorg Med Chem Lett; 2006 Feb; 16(3):554-8. PubMed ID: 16275077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated virtual screening for the identification of novel and selective peroxisome proliferator-activated receptor (PPAR) scaffolds.
    Nevin DK; Peters MB; Carta G; Fayne D; Lloyd DG
    J Med Chem; 2012 Jun; 55(11):4978-89. PubMed ID: 22582973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based design, synthesis, and nonalcoholic steatohepatitis (NASH)-preventive effect of phenylpropanoic acid peroxisome proliferator-activated receptor (PPAR) α-selective agonists.
    Ban S; Kasuga J; Nakagome I; Nobusada H; Takayama F; Hirono S; Kawasaki H; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2011 May; 19(10):3183-91. PubMed ID: 21530275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concise and efficient asymmetric synthesis of (S)-2-ethylphenylpropanoic acid derivatives: dual agonists for human peroxisome proliferator-activated receptor alpha and delta.
    Kasuga J; Hashimoto Y; Miyachi H
    Bioorg Med Chem Lett; 2006 Feb; 16(4):771-4. PubMed ID: 16321522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and evaluation of a novel series of alpha-substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) alpha/delta dual agonists for the treatment of metabolic syndrome.
    Kasuga J; Yamasaki D; Araya Y; Nakagawa A; Makishima M; Doi T; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2006 Dec; 14(24):8405-14. PubMed ID: 16996742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of dual peroxisome proliferator-activated receptors gamma and delta agonists as novel euglycemic agents with a reduced weight gain profile.
    Xu Y; Etgen GJ; Broderick CL; Canada E; Gonzalez I; Lamar J; Montrose-Rafizadeh C; Oldham BA; Osborne JJ; Xie C; Shi Q; Winneroski LL; York J; Yumibe N; Zink R; Mantlo N
    J Med Chem; 2006 Sep; 49(19):5649-52. PubMed ID: 16970391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design.
    Montanari R; Saccoccia F; Scotti E; Crestani M; Godio C; Gilardi F; Loiodice F; Fracchiolla G; Laghezza A; Tortorella P; Lavecchia A; Novellino E; Mazza F; Aschi M; Pochetti G
    J Med Chem; 2008 Dec; 51(24):7768-76. PubMed ID: 19053776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ligand- and structure-based drug design strategies and PPARδ/α selectivity.
    Maltarollo VG; Honório KM
    Chem Biol Drug Des; 2012 Oct; 80(4):533-44. PubMed ID: 22672760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Design and synthesis of peroxisome proliferator-activated receptor (PPAR) delta agonists and its implication to the driving force to elicit PPAR delta selectivity].
    Kasuga J; Oyama T; Nakagome I; Aoyama A; Sako K; Makishima M; Hirono S; Morikawa K; Hashimoto Y; Miyachi H
    Yakugaku Zasshi; 2009 Jun; 129(6):709-18. PubMed ID: 19483413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ombuin-3-O-β-D-glucopyranoside from Gynostemma pentaphyllum is a dual agonistic ligand of peroxisome proliferator-activated receptors α and δ/β.
    Malek MA; Hoang MH; Jia Y; Lee JH; Jun HJ; Lee DH; Lee HJ; Lee C; Lee MK; Hwang BY; Lee SJ
    Biochem Biophys Res Commun; 2013 Jan; 430(4):1322-8. PubMed ID: 23247028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands.
    Seimandi M; Lemaire G; Pillon A; Perrin A; Carlavan I; Voegel JJ; Vignon F; Nicolas JC; Balaguer P
    Anal Biochem; 2005 Sep; 344(1):8-15. PubMed ID: 16038868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
    Shioi R; Okazaki S; Noguchi-Yachide T; Ishikawa M; Makishima M; Hashimoto Y; Yamaguchi T
    Bioorg Med Chem Lett; 2017 Jul; 27(14):3131-3134. PubMed ID: 28539218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural insights into human peroxisome proliferator activated receptor delta (PPAR-delta) selective ligand binding.
    Batista FA; Trivella DB; Bernardes A; Gratieri J; Oliveira PS; Figueira AC; Webb P; Polikarpov I
    PLoS One; 2012; 7(5):e33643. PubMed ID: 22606221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CoMFA analysis of dual/multiple PPAR activators.
    Shah P; Mittal A; Bharatam PV
    Eur J Med Chem; 2008 Dec; 43(12):2784-91. PubMed ID: 18321611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar.
    Ebdrup S; Pettersson I; Rasmussen HB; Deussen HJ; Frost Jensen A; Mortensen SB; Fleckner J; Pridal L; Nygaard L; Sauerberg P
    J Med Chem; 2003 Apr; 46(8):1306-17. PubMed ID: 12672231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.